(Reuters) - Fulcrum Therapeutics Inc said on Wednesday it has started the late-stage trial of its experimental muscle disorder drug, losmapimod, in adults hospitalized with COVID-19.
The company in-licensed losmapimod from GlaxoSmithKline Plc last year after the drug failed to prove more effective than placebo in a large clinical trial in 2015. [bwnews.pr/2VeJvn7]
Fulcrum expects to report topline data in the first quarter of fiscal year 2021.
The late-stage trial will assess the proportion of patients who die or experience respiratory failure by day 28, after receiving daily oral dose of losmapimod along with a standard of care for 14 days.
Losmapimod is being tested by Fulcrum for the treatment of a muscle-wasting disorder called facioscapulohumeral muscular dystrophy.
Reporting By Mrinalika Roy in Bengaluru, Editing by Sherry Jacob-Phillips